The effects of specific KRAS inhibitors, such as AMG-510 and MRTX849 targeting specific G12C mutations (KRASG12C) are being investigated in ongoing clinical trials in non-small cell lung cancer [136]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.